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1. Introduction
===============

RNA viruses replicate as complex distributions of mutant genomes termed viral quasispecies.[@BIB1], [@BIB2], [@BIB3] Quasispecies was developed as a general theory to understand the dynamics of the first replicative molecules in the context of the origin of information and early evolution of life.[@BIB4] Quasispecies dynamics, characterized by a continuous process of mutant generation, competition and selection, has also provided an interpretation of the great adaptive potential of pathogenic RNA viruses, and has evidenced the need to use combination antiviral therapies and to design polyvalent antiviral vaccines for the control of viral disease (review by Domingo *et al*.[@BIB3]). An understanding of quasispecies dynamics has opened new antiviral strategies through virus entry into error catastrophe, also termed lethal mutagenesis (review by Eigen[@BIB5]).

Experiments with the animal pathogen foot-and-mouth disease virus (FMDV) have documented that RNA virus quasispecies may possess a genetic memory of those genomes that were dominant at an earlier phase of their evolution.[@BIB6], [@BIB7], [@BIB8] Memory was detected as minority genomes that replicated in the mutant spectrum of two independent evolutionary lineages of FMDV in cell culture.[@BIB6], [@BIB8] The presence of these replicative memory genomes in viral quasispecies may represent a selective advantage for the virus whenever fluctuating selective pressures occur, for example during prolonged chronic infections.[@BIB9] However, no direct evidence of quasispecies memory *in vivo* has been presented so far.

HIV-1 is a human retroviral pathogen whose populations participate of quasispecies dynamics[@BIB10] (review by Crandall[@BIB11]) and that includes two disparate phases in its replication cycle.[@BIB12] As integrated proviruses, cDNA copies of HIV-1 RNA replicate as cellular genes, with the high fidelity copying inherent to cellular DNA polymerases endowed with proofreading-repair activities and subjected also to post-replicative repair pathways.[@BIB13] Upon expression from integrated sites, viral RNAs are processed to direct the synthesis of multiple proteins to culminate in the formation of retroviral particles whose first replicative step upon entering a new host cell is the error-prone copying of genomic RNA into DNA by the retroviral reverse transcriptase (RT).[@BIB12] This replication cycle favours the existence of a second type of genetic memory in HIV-1 which differs from the replicative memory described for FMDV, a picornavirus whose RNA replication cycle does not include a DNA step. Integrated DNA copies of the HIV-1 genome constitute a reservoir of viral sequences that upon cellular activation can contribute new mutant distributions to the replicating pool of the virus.[@BIB11], [@BIB12] Several anatomical compartments (including lymph nodes) and cell types (resting CD4+ lymphocytes, macrophages, and others) are potential reservoirs for HIV-1.[@BIB14], [@BIB15], [@BIB16] Viruses in reservoirs can evolve more slowly than those circulating in the plasma of the same patient, and they can maintain for months or years the genotype exhibited when they entered the reservoir. This genotype can be either wild-type or drug-resistant, independent of the genotype currently dominant in the plasma.[@BIB17], [@BIB18] Integrated proviruses are not affected by the selective pressure of reverse transcriptase inhibitors (RTI), whilst their expression, following activation of the host lymphocyte, may be sensitive to protease inhibitors (PRI).[@BIB11], [@BIB12] Also, some anatomical sites may provide a barrier to the antiretroviral pressure, due to limited access of some drugs (i.e. PRI).[@BIB17], [@BIB18] Viruses from such reservoirs could re-emerge and occupy the circulating quasispecies as documented by phylogenetic analyses of consensus sequences.[@BIB19] Re-emergence could be a consequence of structured treatment interruptions.[@BIB20], [@BIB21], [@BIB22] [Figure 1](#FIG1){ref-type="fig"} shows a flux diagram of HIV-1 infection that takes into account the different cellular types that contribute to (and can represent sources of) memory in the circulating HIV-1 quasispecies (quantitative data[@BIB23], [@BIB24], [@BIB25], [@BIB26], [@BIB27], [@BIB28]). Here we provide direct experimental evidence of the occurrence of memory in HIV-1 quasispecies, and we present a mathematical model to distinguish replicative memory from transiently non-replicative (or reservoir) memory operative in HIV-1. We discuss the implications of the two types of memory for retrovirus adaptation.Figure 1Flux diagram of quasispecies components in a typical HIV-1 infection and the possible sources of genetic memory. The contribution of different infected cells to the circulating HIV-1 quasispecies is as follows: 98% of the circulating virions are produced by actively replicating CD4+ lymphocytes (which constitute 1% of the total number of CD4+ lymphocytes), about 1% of the virions come from macrophages, another 1% from follicular dendritic cells and, finally, less than 1% are produced upon activation of latently infected CD4+ lymphocytes (which represent 9% of the total number of CD4+ lymphocytes). Most (about 90%) of the CD4+ lymphocytes are infected with defective viruses, and they do not contribute to the circulating quasispecies. These three types of CD4+ lymphocytes are similarly distributed between lymph nodes (98%) and the bloodstream (2%) (based on data from [@BIB23], [@BIB24], [@BIB25], [@BIB26], [@BIB27], [@BIB28], and references therein).

2. Results
==========

2.1. Re-emergence of HIV-1 sequences after prolonged times of infection: non-replicative (or reservoir) memory in HIV-1
-----------------------------------------------------------------------------------------------------------------------

To investigate the existence and putative sources of memory in HIV-1 quasispecies, three patients (referred to as case 1, case 2 and case 3, detailed in [Materials and Methods](#SEC7){ref-type="sec"}) were selected due to their poor response to the therapy and/or the fluctuations observed in their viral load and CD4+ lymphocyte count during their complex treatment histories ([Table 1](#TBL1){ref-type="table"}). The possible contribution of non-replicative (reservoir) memory was studied by means of sequence analysis of retrospective viral samples from two patients (cases 1 and 2). Consensus nucleotide sequences were used to deduce the amino acid substitutions present at each codon of the protease (PR) and the first 220 codons of the RT ([Table 2](#TBL2){ref-type="table"}). Sequential HIV-1 sequences from case 1 showed a progressive accumulation of resistance mutations after a five year exposure to AZT (in monotherapy from April 1992 to December 1995, and in combination with ddI until May 1997). This accumulation of nucleoside-resistance mutations ([Table 2](#TBL2){ref-type="table"}) led to selection of multinucleoside-resistant genomes encoding the insertion T69SSS in sample 5.97. The shift to a HAART combination (d4T+3TC+RTV) resulted in the absence of this insert-containing genotype in a sample collected only two months later. Interestingly, this sample (7.97) and the following one (3.98) exhibited a mutation pattern in the RT very close to that of the first available sample of this patient (11.94). HIV-1 proviral DNA collected in August 1998 conserved some of the mutations found in the RT-coding region prior to May 1997. The re-emergence of the initial genotype is not evident for the consensus sequence of the PR-coding region, although a shift to a consensus sequence lacking the key substitutions N37S and R41K was observed in sample 7.97 ([Table 2](#TBL2){ref-type="table"}). The different behaviour of the RT and PR genes could be due to the absence of a selective pressure acting on the PR, resulting in their independent evolution, or to intra-patient recombination events. Different phylogenetic approaches were used to analyse consecutive consensus sequences in order to evaluate the possibility of a re-emergence of viruses that could have been hidden in cellular or anatomical compartments from November 1994 until July 1997. NJ, UPGMA, MP and ML methods produced the same overall tree topology for consensus sequences of *pol* and *env* regions ([Figure 2(a) and (b)](#FIG2){ref-type="fig"}). The phylogenetic relationships are highly consistent and show a clear separation between two groups of isolates: 7.95/12.95/9.96/5.97/8.98-DNA (genomes with a progressive accumulation of nucleoside analog-resistance mutations, and the proviral sequence), and 11.94/7.97/3.98 (the ancestral genome and those present after its re-emergence).Table 1CD4+ count, viral load and treatment history of the patients included in this studyCD4+ count[a](#TBLFN1){ref-type="table-fn"}CaseSampling date[b](#TBLFN2){ref-type="table-fn"}Sample identification[c](#TBLFN3){ref-type="table-fn"}No.(%)Viral load[a](#TBLFN1){ref-type="table-fn"} (RNA copies/ml)Antiretroviral therapy introduced[a](#TBLFN1){ref-type="table-fn"}13.4.9233826--AZT15.11.9411.9429731\<500AZT27.7.957.95299276240AZT19.12.9512.95208268920AZT+ddI5.9.969.9639030\<500AZT+ddI13.5.975.97297271610d4T+3TC+RTV21.7.977.97245265830d4T+3TC+SQV7.10.9736029\<500d4T+3TC+SQV3.3.983.9841632650d4T+3TC+SQV21.7.9833729\<50d4T+3TC+SQV+NFV11.8.988.98-DNA------d4T+3TC+SQV+NFV15.12.9837730\<50d4T+3TC+IDV11.1.99------d4T+NVP+NFV12.3.9949438\<50d4T+NVP+NFV  212.3.92------AZT23.3.9524011--AZT+ddI21.9.959.9528611--AZT+ddI9.1.9625010--AZT+ddI3.5.961768--AZT+ddC21.5.96------AZT+3TC26.6.96----1,300,000AZT+d4T+3TC6.8.968.961899120,060AZT+d4T+3TC8.1.971688--d4T+3TC+IDV24.4.972619156,150d4T+3TC+IDV19.8.972811026,520d4T+3TC+IDV3.9.97------ddI+d4T+RTV+SQV (Stops all treatment: 26.9-17.10)17.10.9710.97280103730ddI+d4T+RTV+SQV5.1.981.982801035,910ddI+d4T+RTV+SQV (Bad compliance)17.3.98182768,640ddI+d4T+RTV+SQV (Bad compliance)14.5.98----49,020d4T+3TC+RTV+SQV30.7.982007\<500d4T+3TC+NVP+RTV+SQV13.8.988.981827309d4T+3TC+NVP+RTV+SQV (Bad compliance)29.9.989.98234628,420d4T+3TC+NVP+RTV+SQV (Bad compliance)26.10.98------ddI+d4T+NVP+RTV+NFV+HU4.1.991.99----61,050ddI+d4T+NVP+RTV+NFV+HU  36.7.89303----AZT21.9.90252----AZT25.2.93134----AZT4.6.93120----AZT+ddC28.2.941-1 to 1-20102--154,190AZT+ddC16.5.9491----AZT+ddC6.10.9447----AZT+ddC19.1.952-1 to 2-2035--68,630ddI22.6.953-1 to 3-2021--156,210AZT+3TC28.8.954-1 to 4-2030--143,300AZT+3TC26.9.955-1 to 5-2026--162,800AZT+3TC16.5.966-1 to 6-2015--50,100AZT+3TC22.6.9613----AZT+3TC+IDV9.96------Exitus[^2][^3][^4]Table 2Amino acid substitutions found in consensus sequences of the protease (A) and reverse transcriptase (B, C) of sequential HIV-1 samples from cases 1 to 3A. *Protease*Amino acid position[a](#TBLFN4){ref-type="table-fn"}1012141516193235373841465759616263646572737782849093CaseSampleAntiretroviral therapy[b](#TBLFN5){ref-type="table-fn"}LTKIGLVENLRMRYQIPIEIGVVILI111.94AZT----(R)----------S--K----------**L**------------------7.95AZT----------------S--K----------**L**--------(**L**)--------12.95AZT----------------S--K----------**L**------------------9.96AZT+ddI----------------S--K----------**L**------------------5.97AZT+ddI----------------S--K----------**L**------------------7.97d4T+3TC+RTV--------------------------------**L**------------------3.98d4T+3TC+SQV--------------------------------**L**------------------8.98-DNAd4T+3TC+SQV+NFV------------------S----K------**L**------------------  29.95AZT+ddI--------------D--------(K)------------V--**I**------L8.96AZT+d4T+3TC--------------D----------------------V--**I**------L10.97ddI+d4T+RTV+SQV (stopped)------------**I**--------**I**--------------V----**A**----L1.98ddI+d4T+RTV+SQV**I**------------D------**I**------V------V**SI**--**VM**L8.98d4T+3TC+NVP+RTV+SQV------------**I**--------**I**--------------------**A**----L9.98d4T+3TC+NVP+RTV+SQV (b.c.)**I**------------D------**I**------V------V**S**----**VM**L1.99ddI+d4T+NVP+RTV+NFV+HU**I**------------D------**I**------V------V**S**----**VM**L  31 (2.94)AZT+ddC--------E--------------------V**E**L------**I**--------2 (1.95)AZT+ddC--------EV----------------(K)V**C**--------**I**--------3 (6.95)ddI------(L)E--------(P)--------EV**Q**--------**I**--------4 (8.95)AZT+3TC--K--(V)E--------------K--EV**Q**--D----**I**--------5 (9.95)AZT+3TC--------E------------------N,DV**Q**,**H**--(D)----**I**--------6 (5.96)AZT+3TC--------E--------(P)------(S)--V**Q**----(V)--**I**--------B. *Reverse transcriptase (aa 1--120)*  Amino acid position (1--120)[a](#TBLFN4){ref-type="table-fn"}2041464953545761676869ins.7072838890100102103106109118CaseSampleAntiretroviral therapy[b](#TBLFN5){ref-type="table-fn"}KMKKENNFDST--KRRWVLKKVLV111.94AZT------R------S----------------I--R--------7.95AZT------------------------**R**--------------------12.95AZT------------------------**R**--------------------9.96AZT+ddI----------------**N**------**R**(G)------(V)----(**L**)(R)--5.97AZT+ddI(R)**L**----------------**SSSR**------------------(**F**)7.97d4T+3TC+RTV------R--(K)--------------------I--(R)--------3.98d4T+3TC+SQV------R------------------------I------------8.98-DNAd4T+3TC+SQV+NFV------------------------(**R**)--------------------  29.95AZT+ddI----------------**N**------**R**--------------------8.96AZT+d4T+3TC----------------**N**------**R**--------------------10.97ddI+d4T+RTV+SQV (stopped)----------------**N**--**D**--**R**--------------------1.98ddI+d4T+RTV+SQV--**L**------------**N**--**D**------------------------8.98d4T+3TC+NVP+RTV+SQV----------------**N**--**D**--**R**--------------------9.98d4T+3TC+NVP+RTV+SQV (b.c.)--**L**--------S--**N**--**D**----------------**N**----**I**1.99ddI+d4T+NVP+RTV+NFV+HU--**L**------------**N**--**D**----------------------**I**  31 (2.94)AZT+ddC--**L**----------------**SSS**----K----------------2 (1.95)AZT+ddC--**L**(E)--(G)----(S)----**SSS**----KS--------------3 (6.95)ddI--**L**----------(S)----**S**------K----------------4 (8.95)AZT+3TC--**L**--------------(N)**SSG**------S--------------5 (9.95)AZT+3TC--**L**----------------**SSG**------S--------------6 (5.96)AZT+3TC--**L**----------------**SSG**------S--------------C. *Reverse transcriptase (aa 121--220)*  Amino acid position (121--220)[a](#TBLFN4){ref-type="table-fn"}122123125127135162163166169177178184186188196202210211214215CaseSampleAntiretroviral therapy[b](#TBLFN5){ref-type="table-fn"}KDRYTSSKEDIMDYGILRLT111.94AZT--------I------D----------------KF--7.95AZTEN----I------D----------------KF--12.95AZT--------I(C)----D------------------FY9.96AZT+ddI------(F)VC------(E)(M)--------------F**Y**5.97AZT+ddI----(K)--VC(T)----(E)(M)--------------F**Y**7.97d4T+3TC+RTV--------I------------------------KF--3.98d4T+3TC+SQV--------I------D----------------KF--8.98-DNAd4T+3TC+SQV+NFV--------IC------------------------F--  29.95AZT+ddI--------I------------------------KF**Y**8.96AZT+d4T+3TC--------I------------(**V**)----------KF**Y**10.97ddI+d4T+RTV+SQV (stopped)E------I------------**V**----------KF**Y**1.98ddI+d4T+RTV+SQV--------I----------------------**W**KF**Y**8.98d4T+3TC+NVP+RTV+SQVE------I------------**V**----------KF**Y**9.98d4T+3TC+NVP+RTV+SQV (b.c.)--------I------------**V**--------**W**KF**Y**1.99ddI+d4T+NVP+RTV+NFV+HU--------I----------------**L**----**W**KF**Y**  31 (2.94)AZT+ddC------FI----R--N--------E------F**Y**2 (1.95)AZT+ddC------FI----R--------Y--EV----F**Y**3 (6.95)ddI------FI----R------------E------F**Y**4 (8.95)AZT+3TC--------I----R--E--------E------F**Y**5 (9.95)AZT+3TC------FI----R--E--------E------F**Y**6 (5.96)AZT+3TC------FI----R--E--------E------F**Y**[^5][^6][^7]Figure 2Neighbor-Joining trees of *pol* ((a) case 1; (c) case 2) and *env* ((b) case 1; (d) case 2) sequences. Amplification of the *env* region was not possible for samples 7.95 and 9.96 in case 1 (b) and for sample 8.96 in case 2 (d). Bootstrap values (1000 replicas) higher than 0.65 per unit are indicated in parenthesis. Clearly defined groups of sequences have been encircled. The bar represents 0.01 ((a) and (c)) or 0.1 ((b) and (d)) substitutions per nucleotide. Genetic distances can be calculated from the branch lengths; exact values of them will be provided upon request. The same topology was found using other phylogenetic approaches such as UPGMA, maximum parsimony and maximum likelihood (data not shown).

Case 2 was a patient with a poor adherence to treatment, who showed large fluctuations in viral load as a response to different HAART regimes during the period of study ([Table 1](#TBL1){ref-type="table"}). After the interruption of a regime composed of ddI+d4T+RTV+SQV in September 1997, large fluctuations both in viral load and mutational pattern were recorded in consensus sequences from October 1997 to September 1998 ([Table 1](#TBL1){ref-type="table"}, [Table 2](#TBL2){ref-type="table"}). The amino acid substitutions in PR and RT suggested the occurrence of two progressive re-emergence events. Sample 8.98 would be the result of the re-emergence of viruses related to those in sample 10.97 (with some definitory amino acid replacements, such as V32I and V82A in the PR, and K70R and K122E in the RT), and sample 9.98 would result from the re-emergence of sequences from sample 1.98 (with signature substitutions L10I, I62V, G73S, I84V and L90M at the PR, and M41L and L210W at the RT). Most of these amino acid replacements are related to drug resistance to PRI or RTI.[@BIB29], [@BIB30] A phylogenetic analysis of the sequential consensus sequences using MP, NJ, UPGMA and ML indicated isomorphic topologies for *pol* and *env* in all cases ([Figure 2(c) and (d)](#FIG2){ref-type="fig"}). The phylogenies show a clear clustering of samples 10.97/8.98 distant from the cluster formed by samples 1.98/9.98/1.99, consistent with a double process of re-emergence of genomes hidden in reservoirs.

2.2. Replicative memory in HIV-1
--------------------------------

Apart from non-replicative memory due to re-emergence from cellular or anatomic compartments, a replicative memory could also exist in retroviruses, analogous to that previously documented in FMDV.[@BIB6], [@BIB7], [@BIB8], [@BIB9] To evaluate the possible presence of replicative memory in HIV-1, a detailed phylogenetic analysis was performed on sequential clonal sequences from case 3. In this patient, key mutations in HIV-1 related to decreased sensitivity to inhibitors were maintained at all time points, yet dominance of genomes encoding the RT insertion T69SSS was lost within a six month interval (from January to June 1995), probably as a result of the switch from AZT+ddC treatment to ddI monotherapy. The re-introduction of AZT (in combination with 3TC) was associated with selection (from June to August 1995) of a virus whose consensus sequence contained the RT insert ([Table 2](#TBL2){ref-type="table"}). MP analysis of 693 bp long sequences of 120 molecular clones spanning the PR-coding region and the first 130 codons of RT for six sequential samples ([Table 1](#TBL1){ref-type="table"}) using HIV-1 CAM-1 as the reference sequence showed a separation (statistically supported by bootstrap re-sampling) between sequences harbouring the dipeptide insertion (either Ser-Ser or Ser-Gly) and those without any RT insertion ([Figure 3](#FIG3){ref-type="fig"}). Sample 2, which as sample 1 had a consensus sequence with T69SSS RT ([Table 2](#TBL2){ref-type="table"}), contained one clone (2-17) without insertion, which clustered with all clones (except three) from sample 3. Conversely, sample 3, with a consensus sequence without RT insertion ([Table 2](#TBL2){ref-type="table"}), harboured three clones (3-3, 3-5 and 3-8) with a T69SSS genotype. These minority sequences from sample 3 clustered with all the insert-containing sequences from samples 4, 5, and 6. Therefore, minority genomes without insertion were present in populations dominated by insertion-coding genomes, and, conversely, minority insertion-coding genomes were present in populations dominated by viruses devoid of the insertion. These results suggest the presence of a replicative memory in HIV-1 quasispecies.Figure 3Maximum parsimony clustering of the 120 sequences of molecular clones from six sequential samples from case 3, using HIV-1 CAM-1 as reference sequence.[@BIB50] Unique sequences are identified as sample-clone number (see [Table 1](#TBL1){ref-type="table"}). Groups of clones with identical sequences are labelled as sample-letter-number: the letter is consecutive for each group in one sample and the number indicates how many identical clones belong to that group. Sample 1 (February 1994) showed four groups of identical sequences: 1-A5 (clones 1-1, 1-4, 1-7, 1-14 and 1-16), 1-B3 (1-3, 1-9 and 1-12), 1-C3 (1-8, 1-18 and 1-19) and 1-D2 (1-13 and 1-15). Samples 2 (January 1995) and 3 (June 1995) had all their clonal sequences different from each other. Sample 4 (August 1995) showed five groups of identical sequences: 4-A3 (4-2, 4-6 and 4-20), 4-B2 (4-4 and 4-12), 4-C2 (4-7 and 4-16), 4-D2 (4-8 and 4-9) and 4-E3 (4-10, 4-14 and 4-15). Sample 5 (September 1995) had three groups of identical sequences: 5-A2 (5-4 and 5-12), 5-B2 (5-7 and 5-20) and 5-C2 (5-14 and 5-18). Sample 6 (May 1996) showed one group of identical sequences: 6-A2 (6-4 and 6-5). Therefore, the 120 clones were represented by 100 different sequences in the clustering. Five defective clones detected in sample 5 were 5-2, 5-9, 5-11 and those in group 5-C2. Colour code: blue, sequences with the RT insertion T69SSS; green, sequences with the RT insertion T69SSG; red, sequences without RT insertions. Asterisks indicate clusters for which a bootstrap analysis (1000 replicas) gave a significance higher than 0.98 per unit. Minority sequences in samples 2 (2-17) and 3 (3-3, 3-5 and 3-8) have been underlined.

2.3. Quantitative model of quasispecies dynamics involving replicative and non-replicative memory
-------------------------------------------------------------------------------------------------

The results of sequential analyses of HIV-1 sequences from three patients ([Table 1](#TBL1){ref-type="table"}, [Table 2](#TBL2){ref-type="table"}, and [Figure 2](#FIG2){ref-type="fig"}, [Figure 3](#FIG3){ref-type="fig"}) suggest that both a replicative memory of the type described previously for FMDV,[@BIB6], [@BIB8] together with a non-replicative (or reservoir) memory are in operation during HIV-1 replication *in vivo*. In order to describe quantitatively these two types of memory, we made use of a mathematical model based on the theory of quasispecies[@BIB4], [@BIB31], [@BIB32] involving a three-component system. Although some very detailed models of the dynamics of HIV-1 infection (considering the immune response of the host) have been developed[@BIB23], [@BIB28], [@BIB33], [@BIB34], [@BIB35], [@BIB36], [@BIB37], [@BIB38], [@BIB39], [@BIB40], [@BIB41], [@BIB42], [@BIB43] we have focused here on viral quasispecies dynamics with regard to the emergence of replicative and non-replicative memory.

We consider a population with three different viral components *j*∈{1,2,3} and denote by *n* ~*j*~(*t*) the number of viruses of component j at time *t*, and by *k* ~*j*~ the rate of reproduction of component j (the viruses of type j reproduce at a constant rate, given by *k* ~*j*~ offspring per parent per unit time). We introduce the quality factor *q* ~*j*~ (*q* ~*j*~∈\[0,1\]): the fraction of faithful copies of *j*; the rest, 1−*q* ~*j*~, are mutants from j to other components *k*. The constant rate of mutation from j to k is termed μ~*kj*~. We assume μ~*kj*~ to be a constant μ~*kj*~=μ, with μ in the range from 10^−5^ to 10^−3^. The differential equation satisfied by *n* ~*j*~(*t*), assuming a constant population size and no degradation, is:[@BIB4], [@BIB31], [@BIB32] where ∑j=13nj(t)=κ is the total population size, k̄(t)=∑j=13kjnj(t)/κ, and the rates of reproduction, quality factors, and mutation rates are not independent quantities, but are related by the identity:In the case of three viral species, and from [equality (2)](#FD2){ref-type="disp-formula"}, we have: where:In the case of only two species contributing to the quasispecies, the equations are slightly different, and [condition (2)](#FD2){ref-type="disp-formula"} implies: The system of [equation (1)](#FD1){ref-type="disp-formula"} can be written in a more compact form: ṅ=Mn−k̄1n, where the dot means a time derivative, and we have introduced the matrix *M*. We are interested in the steady-state quasispecies solution.[@BIB31] A solution is provided by diagonalizing the matrix *M*, which means finding a diagonal matrix λ and a non-singular matrix *O*, such that λ=*OMO* ^−1^ and *M*=*O* ^−1^λ*O*. If the quasispecies is made up of N different components, the late time limit of *n* ~*j*~(*t*), which we denote by n̄j, is given by:where we have assumed that component 1 of the quasispecies is fitter than the rest *N*−1 (*k* ~1~\>*k* ~*j*~\>0). The columns of the matrix *O* ^−1^ correspond to the components of the eigenvectors of *M*. Therefore, the computation of the relative fractions (given by [equation (8)](#FD8){ref-type="disp-formula"}) requires only the largest eigenvalue λ~1~ and its corresponding eigenvector v̂1, which is the first column of the matrix *O* ^−1^.

In the case *N*=2, the eigenvalue equation is the polynomial:with *m* ~11~=*k* ~1~−μ, *m* ~12~=μ, *m* ~21~=μ, and *m* ~22~=*k* ~2~−μ.

The relative fractions of the quasispecies are given by (as by Ruíz-Jarabo *et al*.[@BIB8]): In the case *N*=3, the matrix M that needs to be diagonalized is:The corresponding eigenvalue equation is:where the coefficients are given by: The solution for the largest eigenvalue, λ~1~, is given by:with *Q*=(3*A* ~1~−*A* ~2~ ^2^)/9 and cos θ=−R/−(Q3), where *R*=(9*A* ~2~ *A* ~1~−27*A* ~0~−2*A* ~2~ ^3^)/54. In terms of this eigenvalue the relative fractions of the steady-state quasispecies are given by: A numerical approach allowed solving the system of differential equations ([(6)](#FD6){ref-type="disp-formula"}, [(7)](#FD7){ref-type="disp-formula"} in the case *N*=2, and [(3)](#FD3){ref-type="disp-formula"}, [(4)](#FD4){ref-type="disp-formula"}, [(5)](#FD5){ref-type="disp-formula"} in the case *N*=3) given initial and intermediate conditions. We start at time *t* ~0~ with only viral components 1 and 2 present, at arbitrary initial conditions *n* ~1~(*t* ~0~) and *n* ~2~(*t* ~0~), respectively (the late time limit does not depend on the initial conditions). Rates of reproduction are *k* ~1~=1.0\>*k* ~2~ (all values of *k* ~*i*~ are relative to the highest one, which is always considered as *k*=1.0). From time *t* ~0~ to time *t* ~1~ we let the system evolve, and assume that *t* ~1~ is sufficiently late so that n1(t1)=n̄1 and n2(t1)=n̄2 are the quasispecies values for the corresponding choice of parameters *k* ~1~ and *k* ~2~, respectively. The evolution from *t* ~1~ to *t* ~2~ is characterized by n̄1 and n̄2. At a later time *t* ~2~ the system is exposed to a selective pressure, with component 1 being affected and component 2 not affected. In the particular case of dynamics of HIV-1 *in vivo* such selective pressure can be identified with an antiviral treatment, so that 1 is sensitive to the treatment, whereas 2 is resistant. This corresponds to the situation *k* ~2~=1.0\>*k* ~1~. After a short period δ, that is, at *t* ~2~+δ, the selective pressure is withdrawn, expecting to recover *k* ~1~=1.0\>*k* ~2~, with *k* ~2~ at *t* ~2~+δ being larger than the initial *k* ~2~ value at *t* ~0~, which means that component 2 has become fitter. With these new values for *k* ~1~ and *k* ~2~ we let the system evolve to a sufficient late time *t* ~3~. At *t* ~3~, *n* ~1~(*t* ~3~) and *n* ~2~(*t* ~3~) have reached their new quasispecies values (as the value of the constants has changed). In particular, n̄1(t3)\<n̄1(t1) and n̄2(t3)\>n̄2(t1). The value n̄2(t3)/κ corresponds to the level of "molecular" or replicative memory of component 2. The evolution from *t* ~3~ to *t* ~4~ is characterized by these quasispecies values. At a later time *t* ~4~ we apply a second selective pressure (a different antiviral treatment), which favours a new component 3 to move from a reservoir to the bloodstream (thus the circulating quasispecies includes now three components). We assume that component 1 is sensitive to the treatment, components 2 and 3 are resistant, and 3 is fitter than 2 (this is the reason why component 3 has moved from a reservoir compartment to the bloodstream), so *k* ~3~=1.0\>*k* ~2~\>*k* ~1~. If this second treatment is maintained after *t* ~4~, component 3 will remain the majority in the quasispecies, and will be recognized as the consensus sequence. This corresponds to the situation reported for cases 1 and 2, where the re-emergence of ancestral "component 3" genomes was detected as the consensus sequence, following a long dominance of "component 1" genomes. If we discontinue this second treatment at a time *t* ~4~+δ, the system will recover the fitness ratio *k* ~1~=1.0\>*k* ~3~\>*k* ~2~ and, at a later time *t* ~5~, sufficient for the system to reach its steady-state, we will obtain new quasispecies values for this set of parameters: n̄1(t5), n̄2(t5) and n̄3(t5). The quasispecies level n̄3(t5)/κ would correspond to the contribution of non-replicative (or reservoir) components to the quasispecies memory.

We have run three numerical computations corresponding to three different values of the mutation rate, namely μ=10^−3^, 10^−4^ and 10^−5^. [Figure 4](#FIG4){ref-type="fig"} depicts one example of the time evolution of the system for μ=10^−3^. Therefore, the theoretical treatment of quasispecies dynamics permits modelling of two types of memory during HIV-1 replication, in agreement with experimental analyses of HIV-1 genome evolution in patients undergoing antiretroviral therapy.Figure 4Dynamics of three-component viral quasispecies. The plot gives relative fractions of viral components (*n*~*j*~(*t*)/κ) as a function of time for μ=10^−3^. The left *y* axis corresponds to *n*~1~(*t*)/κ (green lines), and the right *y* axis corresponds to both *n*~2~(*t*)/κ (blue lines) and *n*~3~(*t*)/κ (pink lines). Notice the different scales on the left and right y axes. Values at the right y axis decrease by a power of 10 each time μ decreases by a power of 10 (simulations with μ=10^−4^ and μ=10^−5^, not shown). The parameters chosen for this simulation are as follows: at time *t*~0~=0, *n*~1~(*t*~0~)=500, *n*~2~(*t*~0~)=500, *k*~1~=1.0 and *k*~2~=0.02; at time *t*~1~=250 the system has reached its steady-state (corresponding to the values of *k*~*j*~ at *t*~0~); at time *t*~2~=350, the two-component system is exposed to a selective pressure (antiviral treatment) and *k*~1~=0.01 and *k*~2~=1.0; at time *t*~2~+δ=370 the selective pressure is switched off and *k*~1~=1.0 and *k*~2~=0.2; at time *t*~3~=620 the system has reached its steady-state (corresponding to the values of *k*~*j*~ at *t*~2~+δ), and the value of *n*~2~(*t*~3~)/κ corresponds to the level of replicative memory of component 2 (which has a level of 1.02×10^−3^ in this example, with μ=10^−3^); at time *t*~4~=720 the system is exposed to a second selective pressure (a different antiviral treatment) that forces a new component 3 to move from a reservoir to the bloodstream (the initial condition for component 3 was chosen as *n*~3~(*t*~4~)=10^−4^\[*n*~1~(*t*~4~)+*n*~2~(*t*~4~)\]), and *k*~1~=0.03, *k*~2~=0.3, *k*~3~=1.0; at time *t*~4~+δ=740 the selective pressure is switched off and *k*~1~=1.0, *k*~2~=0.15, and *k*~3~=0.25; at time *t*~5~=990 the system has reached its steady-state (corresponding to the values of *k*~*j*~ at *t*~4~+δ), and the value of *n*~3~(*t*~5~)/κ reflects the contribution of non-replicative (or reservoir) components to the quasispecies memory (which has a level of 1.17×10^−3^ in this simulation, with μ=10^−3^).

3. Discussion
=============

The presence of memory genomes in viral quasispecies, documented with designed experiments employing FMDV,[@BIB6], [@BIB8], [@BIB9] is an expected consequence of quasispecies dynamics.[@BIB9], [@BIB31], [@BIB44], [@BIB45], [@BIB46] For retroviruses such as HIV-1, the level of complexity of the replicating quasispecies at any one time is expected to be greater than for non-retroviral riboviruses because proviral sequences (maintained with the minimal occurence of point mutations associated with cellular genes)[@BIB13] can be activated to perturb the dynamics of replicating retroviral particles. Evidence of re-emergence of ancestral viral sequences was previously obtained for HIV-1,[@BIB19], [@BIB21], [@BIB47] hepatitis C virus[@BIB48] and hepatitis B virus[@BIB49] (review by Domingo *et al*.[@BIB3]).

Phylogenetic methods have been extensively applied to the molecular epidemiology of viruses, including the origin of HIV, its spread to different geographical areas, and the impact of viral mutation, recombination and host interactions on HIV-1 population dynamics.[@BIB50], [@BIB51], [@BIB52], [@BIB53], [@BIB54], [@BIB55], [@BIB56] In the present study we have used such procedures to provide evidence for the presence of memory in HIV-1 quasispecies from three patients subjected to successions of well defined selective antiviral pressures. Case 1 documented the re-emergence of viral genomes that could have been hidden in cellular or anatomical body compartments for 32 months. These memory viruses lacked all the nucleoside resistance mutations, including the insertion T69SSS, that had progressively accumulated in the circulating quasispecies. The introduction of a potent HAART regime (d4T+3TC+RTV) would have eliminated most of the circulating viruses while ancestral, probably fitter, viruses would have moved from the reservoirs to the bloodstream. A previous clonal analysis[@BIB51] did not provide evidence that minority members of the replicating quasispecies survived the treatment, although such minority could have been below the detection level of the analysis. Case 2 revealed that re-emergence of viral genomes can occur in two consecutive rounds, as a result of treatment interruption or incomplete adherence. In case 3, MP analysis of molecular clones indicated that minority genomes without an RT insertion in sample 2 (5% of the total quasispecies) became majority (85%) in sample 3, probably due to their higher fitness after six months in the absence of AZT+ddC therapy and in the presence of ddI. Minority genomes that maintained the T69SSS genotype in sample 3 (15% of the total quasispecies) were likely selected by the re-introduction of AZT (together with 3TC) and restored a quasispecies dominated by viruses with the RT insertion in sample 4 (collected two months after sample 3; [Table 1](#TBL1){ref-type="table"}). The inserts in RT were probably maintained during the rest of the infection due to the multi-nucleoside resistance they confer to HIV-1.[@BIB57], [@BIB58], [@BIB59], [@BIB60] Therefore, minority components of the mutant spectra of a HIV-1 quasispecies can be maintained in memory as a record of the previous evolutionary history, and can become dominant when the same (or a similar) selective pressure that originated them is reintroduced. The case analysed here has shown the presence of minority memory genomes in samples 2 and 3 that then originated the majority of mutant spectrum in samples 3 and 4, respectively.

These experimental results strongly suggest the participation of memory genomes in successive dominances of different mutant distributions. The presence of memory HIV-1 genomes, harbouring constellations of mutations associated with resistance to antiretroviral inhibitors different from those mutations present in dominant genomes, confer the virus a selective advantage to respond more rapidly whenever a change in treatment is implemented. Probably, inhibitor-based environmental fluctuations favoured the identification of the two kinds of memory genomes in the cases studied. However, it must be considered that other environmental fluctuations (either internal, due to physiological alterations, or external, such as treatment interruptions) may also favour memory genomes as selective reservoirs to gain dominance in the replicating pool of viruses.

The mathematical model developed here contemplates both the replicative and non-replicative (or reservoir) memory. It is based on the theory of quasispecies, and considers a three-component model in which the third component comes from a latent reservoir after activation by a biological stimulus (opportunistic pathogen or other). The distinction between the contributions of both memory sources is not obvious, because the irruption of a third (non-replicative) component from the latent reservoir may resemble the rise of a replicative minority genome to participate in the multi-component dynamics of the circulating HIV-1 quasispecies. The numerical solution of the time evolution of the system of equations (involving the three components) has shown that both replicative and non-replicative memory produce minority genomes in the steady- state, which to a first approximation (due to the small value of μ when compared to *k* ~*j*~) are proportional to μ (for μ=10^−3^, they are 1.02×10^−3^ and 1.17×10^−3^, respectively; [Figure 4](#FIG4){ref-type="fig"}). Nevertheless, the mathematical model is an approximation without a dynamical mechanism for *k* ~*j*~, which could be relevant for the quasispecies dynamics *in vivo*.

Despite the fact that reservoir memory has its most immediate consequences in the replicative dynamics of retroviruses, it must be pointed out that its implications may extend to other RNA viruses whenever multiple replication sites occur within an organism. Some RNA viruses appear to be highly monotropic, such as human hepatitis viruses, which replicate mainly in hepatocytes (reviews of viral systems see Domingo[@BIB56]). However, other RNA viruses (several picornaviruses, flaviviruses, coronaviruses, etc.) may target different organs and cell subsets providing a complex mosaic of quasispecies distributions. Our model will apply whenever slower replicating mutant distributions can increase their replication rate (for example, as a result of immune-escape or local physiological alterations that increase permissivity to viral replication) and enter into competition with other mutant distributions. Additional studies on quasispecies memory of non-retroviral RNA viruses *in vivo* are needed before applicability of the model presented here can be assessed.

These results with HIV-1 emphasize that mutant spectra in evolving quasispecies may not only be representations of mutant distributions generated as a result of mutational pressure and relative fitness of the mutants generated, but may also include some history-dependent sub-structuring in the composition of genomes. From a practical point of view, this encourages the development of analytical procedures to determine at any one time not only the dominant genomic sequences but also minority genomes that may reflect the evolutionary history of the virus and that may provide the basis for rapid adaptation.[@BIB61] Microarray-based technologies offer the potential to detect minority sequences that are in the range of 0.1--1% in a genome population.[@BIB62], [@BIB63], [@BIB64] In the case of HIV-1 this can have a predictive value regarding treatment efficacy.

4. Materials and Methods {#SEC7}
========================

4.1. Virus samples
------------------

HIV-1 samples were obtained from three patients undergoing highly active antiretroviral therapy (HAART) at Hospital Carlos III in Madrid, Spain. All of them were infected by B subtype strains of HIV-1, and they were not linked epidemiologically. The patient in case 1 was an intravenous drug user born in 1962 who became HIV-1 seropositive during the period 1980--1984. The patient in case 2 was born in 1958 and was infected by homosexual intercourse at some undetermined time before 1992. The patient in case 3 was a haemophiliac man born in 1970, infected at the age of 12 after receiving contaminated blood products.

Sequential retrospective samples from these three patients were collected, and plasma viremia was quantified using the Quantiplex bDNA assay[@BIB65] (Bayer, Barcelona, Spain), with detection limits of 500 and 50 HIV-RNA copies/ml (versions 2.0 and 3.0, respectively). The CD4+ count was measured by flow cytometry (Coulter, Madrid, Spain).

4.2. RNA extraction, reverse transcription, PCR amplification and nucleotide sequencing
---------------------------------------------------------------------------------------

Viral RNA was extracted from plasma samples by a silica-based method.[@BIB66] HIV-1 RNA was reverse-transcribed by AMV RT (Promega, Madison, WI) using either the primer NE135 (reverse 5′-CTTACTAACTTCTGTATGTCATTGACAGTCCAGCT-3′, the 5′ residue corresponds to position 3336 of HIV-1 CAM-1 genome[@BIB50]) for the *pol* gene, or the primer ED12m (reverse 5′-AGTGCTTCCTGCTGCTCCCAAGAACCCAA-3′, the 5′ residue corresponds to position 7812 of HIV-1 CAM-1) for the *env* gene. When appropriate, proviral DNA was extracted from peripheral blood mononuclear cells (PBMCs) by lysis with non-ionic detergents (Tween 20 and NP40) and proteinase K.

Nested PCR was used to amplify two fragments of the HIV-1 genome: (a) a region of 1086 bp of the *pol* gene including 18 bp preceding the start of the PR-coding region, the entire PR-coding region and the first 220 codons of the RT; (b) a region of 368 bp of the *env* gene including the hypervariable V3 loop of the gp120 protein. External primers used to amplify the *pol* region were PRF1 (forward 5′-CAGCCCCACCAGAAGAGAGC-3′,5′ at position 2158 of HIV-1 CAM-1) and NE135, and the inner primers were PRF2 (forward 5′-CAGAAGAAAGCTTCAGGTTTGGG-3′,5′ at position 2167 of HIV-1 CAM-1) and RT4 (reverse 5′-AGTTCATAACCCATCCAAAG-3′, 5′ at position 3252 of HIV-1 CAM-1). Amplification of the *env* region was carried out with the external primers JA19d (forward 5′-CACAGTACAATGTACACATG-3′, 5′ at position 6957 of HIV-1 CAM-1) and ED12m, and the inner ones 6601d (forward 5′-AATGGCAGTCTAGCAGAAG-3′, 5′ at position 7012 of HIV-1 CAM-1) and ED33 (reverse 5′-TTACAGTAGAAAAATTCCCCTC-3′, 5′ at position 7379 of HIV-1 CAM-1). All PCR reactions were performed using the high-fidelity, thermostable *Pfu* DNA polymerase (Promega, Madison, WI) according to the manufacturer\'s protocol.

Consensus nucleotide sequences were determined in both strands of purified, PCR-amplified DNA using the ABI PRISM BigDye Terminator Cycle Sequencing kit (Applied Biosystems, Foster City, CA). Sequences of the *pol* fragment were obtained with the forward primers PRF2 and 55F (5′-CAAAAATTGGGCCTGAAAATCC-3′,5′ at position 2694 of HIV-1 CAM-1), and the reverse ones 51R (5′-ATTGTATGGATTTTCAGGCCC-3′, 5′ at position 2722 of HIV-1 CAM-1) and RT4. Sequences of the *env* region were obtained with the primers 6601d and ED33. Sequence alignments and assemblies into 975--981 bp (*pol*) and 306--315 bp (*env*) contigs were performed by means of the Lasergene v5.0 package (DNASTAR Inc, Madison, WI). Nucleotide sequences have been deposited in the GenBank database with accession numbers AY188555 to AY188581. Nucleotide sequencing of 120 molecular clones of six sequential samples extracted from case 3 (see [Table 1](#TBL1){ref-type="table"}) were described elsewhere,[@BIB51] and GenBank accession numbers of these sequences are AF168235 to AF168354.

4.3. Phylogenetic methods
-------------------------

Multiple alignments of consensus sequences and molecular clones were carried out with the program CLUSTAL W,[@BIB67] using HIV-1 CAM-1 (GenBank accession number D10112)[@BIB50] as the reference sequence. Evolutionary distances were estimated by the program DNADIST from the PHYLIP v3.5 package,[@BIB68] using the Kimura 2-parameter correction method that weighs transitions and transversions at 2:1. Tree topology was inferred by the Neighbor-Joining method (NJ)[@BIB69] using the program NEIGHBOR from PHYLIP v3.5. The topology of the trees was also determined by a different distance-based cladistic method, the "Unweighted Pair Group Method With Arithmetic Mean" (UPGMA)[@BIB70] using NEIGHBOR from PHYLIP v3.5.

Alternative procedures were used for measuring genetic relatedness among samples. Maximum parsimony (MP) methods (program DNAPARS from PHYLIP v3.5 package) were used to construct the tree topology that required the least number of sequence changes from one node to another.[@BIB71], [@BIB72], [@BIB73] Bootstrap re-sampling (1000 data sets) of the multiple alignment was used to test the statistical robustness of the trees obtained by NJ, UPGMA and MP methods.[@BIB74] Maximum likelihood (ML) trees were generated by the program PUZZLE,[@BIB75] using the Tamura-Nei substitution model[@BIB76] and the Gamma distributed rates with eight parameters (TN-8Γ) as heterogeneity model. The TN-8Γ model has been applied to phylogenetic analysis of human retroviruses.[@BIB52], [@BIB77]

4.4. Numerical methods
----------------------

A code written in C was developed to solve numerically the system of differential equations of the mathematical model. It incorporates a Runge--Kutta solver of second order[@BIB78], [@BIB79] and run on a Linux workstation.
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[^1]: Present address: C. Molina-París, Applied Mathematics Department, University of Leeds, Leeds LS2 9JT, UK.

[^2]: Abbreviations: --, not determined; AZT, zidovudine; ddI, didanosine; ddC, zalcitabine; d4T, stavudine; 3TC, lamivudine; RTV, ritonavir; SQV, saquinavir; NFV, nelfinavir; IDV, indinavir; NVP, nevirapine; HU, hydroxyurea.

[^3]: Sampling dates are written as day.month.year.

[^4]: All samples were of viral RNA, except sample 8.98-DNA from case 1, which corresponds to a proviral DNA extracted from PBMCs. Sample identification is written as month.year in cases 1 and 2, and sample-clone number in case 3.

[^5]: Sample identification, treatment history and clinical events of the patients are summarized in [Table 1](#TBL1){ref-type="table"}.

[^6]: The single letter amino acid (aa) code is used. Dash means no change relative to the reference HIV-1 sequence shown at the top (HIV-1 CAM-1 strain, GenBank accession number D10112).[@BIB50] Amino acids in parenthesis indicate that the residue is found in a mixture with the amino acid of the reference sequence shown at the top in a proportion of about 50% (range 40--60% according to the sequence peak pattern). Data from cases 1 and 3 are adapted from Briones *et al*.[@BIB51] Amino acid substitutions at positions relevant to resistance to PRI or RTI have been highlighted with bold-face letters.[@BIB29], [@BIB30]

[^7]: Current therapy at the sampling date is indicated. Abbreviation: b.c., bad compliance. Dates of antiretroviral therapy introduction and drugs abbreviations are shown in [Table 1](#TBL1){ref-type="table"}.
